MEI PHARMA, INC.

Analyst Reco. MEI Pharma, Inc. Börse Stuttgart

Equities

MMI0

US55279B3015

Market Closed - Börse Stuttgart Other stock markets 08:25:57 14/04/2023 pm IST			5-day change	1st Jan Change
4.272 ^EUR	+0.38%		+1,961.78%	+1,757.39%

09/05	MEI Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024	CI
11/04	MEI Pharma, Inc. Announces Strategic Plan to Leverage Recent Positive Voruciclib and ME-344 Clinical Data	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Stifel Adjusts Price Target on MEI Pharma to $7 From $8, Keeps Hold Rating	14/02	MT
Stifel Adjusts Price Target on MEI Pharma to $9 From $10, Maintains Hold Rating	27/23/27	MT
Stifel Adjusts MEI Pharma's Price Target to $10 From $0.50, Keeps Hold Rating	12/23/12	MT
Stifel Nicolaus Adjusts MEI Pharma Price Target to $0.50 From $2, Maintains Hold Rating	13/23/13	MT
HC Wainwright Adjusts Price Target on MEI Pharma to $2 From $5, Maintains Buy Rating	13/23/13	MT
Jefferies Downgrades MEI Pharma to Underperform From Hold, Adjusts Price Target to $0.10 From $0.40	08/23/08	MT
BTIG Downgrades MEI Pharma to Neutral From Buy	06/22/06	MT
Truist Securities Downgrades MEI Pharma to Hold From Buy	06/22/06	MT
Brookline Capital Markets Adjusts MEI Pharma Price Target to $15 From $20, Maintains Buy Rating	25/22/25	MT
BTIG Adjusts MEI Pharma's Price Target to $4 From $11, Reiterates Buy Rating	25/22/25	MT
Truist Securities Adjusts MEI Pharma's Price Target to $3 From $8, Reiterates Buy Rating	25/22/25	MT
Wells Fargo Downgrades MEI Pharma to Equalweight From Overweight, Adjusts Price Target to $2 From $13	25/22/25	MT
HC Wainwright Adjusts MEI Pharma's Price Target to $5 From $10, Reiterates Buy Rating	25/22/25	MT
Stifel Lowers MEI Pharma to Hold From Buy, Price Target to $2 From $6	25/22/25	MT
Jefferies Cuts MEI Pharma to Hold From Buy, Price Target to $1 From $4	25/22/25	MT
Jefferies Starts MEI Pharma at Buy With $4 Price Target	03/22/03	MT
MEI Pharma Says Treatment With Follicular Lymphoma Drug Candidate Shows Complete Response Rate of Over 35% in Mid-Stage Trial	30/21/30	MT
MEI Pharma Announces Pre-Specified Response Rate Exceeded in Dose-Escalation Study of Me-401 in Chronic Lymphocytic Leukemia and Follicular Lymphoma	31/17/31	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Secure and Increase the Performance of your Investments with our Team of Experts at your Side

Securing my Investments

fermer